Metabolic and anthropometric changes one year after switching from Didanosine/Stavudine to Tenofovir in HIV-infected patients

European Journal of Medical Research

Volumn 12, Issue 2, 2007, Pages 54-60

  Class, G J ^a   Julg B ^a   Roling J ^a   Goebel, F D ^a   Bogner, Johannes R ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cholesterol; Didanosine; hba1c; Lactate; Lipodystrophy; Nucleoside analogues; Renal function; Stavudine; Switch; Tenofovir; Triglycerides; Uric acid

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; DIDANOSINE; HEMOGLOBIN A1C; LACTIC ACID; STAVUDINE; TENOFOVIR; URIC ACID;

ADULT; AGED; ANTHROPOMETRY; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SUBSTITUTION; DYSLIPIDEMIA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; KIDNEY FUNCTION; LACTATE BLOOD LEVEL; LIPODYSTROPHY; LYMPHOCYTE COUNT; MALE; MONOTHERAPY; SIDE EFFECT; SKINFOLD THICKNESS; URIC ACID BLOOD LEVEL; VIRUS LOAD;

ADENINE; ADULT; AGED; ANTI-HIV AGENTS; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CREATININE; DIDANOSINE; FEMALE; GLOMERULAR FILTRATION RATE; HEMOGLOBINS; HIV INFECTIONS; HUMANS; LACTIC ACID; MALE; MIDDLE AGED; PHOSPHATES; PHOSPHONIC ACIDS; SKINFOLD THICKNESS; STAVUDINE; TREATMENT OUTCOME; TRIGLYCERIDES; URIC ACID; VIRAL LOAD;

EID: 33947184358     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Badiou S, Merle De BC, Terrier N, Baillat V, Cristol JP, Reynes J. Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-positive adults? J Infect 2005.
2. Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 46: 716-23, 2002.
3. Blanco F, Garcia-Benayas T, Jose de la CJ, Gonzalez-Lahoz J, Soriano V. First-line therapy and mitochondrial damage: different nucleosides, different findings. HIV Clin Trials 4: 11-9, 2003.
4. Callens S, De RA, Colebunders R. Fanconi-like syndrome and rhabdomyolysis in a person with HIV infection on highly active antiretroviral treatment including tenofovir. J Infect 47: 262-3, 2003.
5. Carr A. Lactic acidemia in infection with human immunodeficiency virus. Clin Infect Dis 36: S96-S100, 2003.
6. Carr A, Morey A, Mallon P, Williams D, Thorburn DR. Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia. Lancet 357: 1412-4, 2001.
7. Coca S, Perazella MA. Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci 324: 342-4, 2002.
8. Creput C, Gonzalez-Canali G, Hill G, Piketty C, Kazatchkine M, Nochy D. Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS 17: 935-7, 2003.
9. d'Arminio A, Sabin CA, Phillips AN, Reiss P, Weber R, Kirk O, El-Sadr W, De WS, Mateu S, Petoumenos K, Dabis F, Pradier C, Morfeldt L, Lundgren JD, Friis-Moller N. Cardio- and cerebrovascular events in HIV-infected persons. AIDS 18: 1811-7, 2004.
10. Domingo P, Labarga P, Palacios R, Guerro MF, Terron JA, Elias MJ, Santos J, Ruiz MI, Llibre JM. Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results. AIDS 18: 1475-8, 2004.
11. Earle KE, Seneviratne T, Shaker J, Shoback D. Fanconi's syndrome in HIV+ adults: report of three cases and literature review. J Bone Miner Res 19: 714-21, 2004.
12. Escolano Hortelano CM, Ramos Rincon JM, Gutierrez RF, Masia CM, Hernandez A, I, Benito SC, Padilla US, Martin-Hidalgo A. [Changes in the spectrum of morbidity and mortality in hospital admissions of HIV infected patients during the HAART era]. Med Clin (Barc) 122: 1-5, 2004.
13. Falco V, Rodriguez D, Ribera E, Martinez E, Miro JM, Domingo P, Diazaraque R, Arribas JR, Gonzalez-Garcia JJ, Montero F, Sanchez L, Pahissa A. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis 34: 838-46, 2002.
14. Friis-Moller N, Sabin CA, Weber R, d'Arminio MA, El-Sadr WM, Reiss P, Thiebaut R, Morfeldt L, De WS, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349: 1993-2003, 2003.
15. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292: 191-201, 2004.
16. Galli M, Ridolfo AL, Adorni F, Gervasoni C, Ravasio L, Corsico L, Gianelli E, Piazza M, Vaccarezza M, d'Arminio MA, Moroni M. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 29: 21-31, 2002.
17. Jones R, Sawleshwarkar S, Michailidis C, Jackson A, Mandalia S, Stebbing J, Bower M, Nelson M, Gazzard BG, Moyle GJ. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone. HIV Med 6: 396-402, 2005.
18. Julg BD, Bogner JR, Crispin A, Goebel FD. Progression of renal impairment under therapy with tenofovir. AIDS 19: 1332-3, 2005.
19. Kabadi UM, Gopal V, Hood L, Kabadi MU, Platt K. Elevated glycosylated hemoglobin concentrations in AIDS. AIDS 6: 236-8, 1992.
20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461-70, 1999.
21. Llibre JM, Domingo P, Palacios R, Santos J, Perez-Elias MJ, Sanchez-de la RR, Miralles C, Antela A, Moreno S. Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir. AIDS 20: 1407-14, 2006.
22. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 14: 1309-16, 2000.
23. Martin A, Smith DE, Carr A, Ringland C, Amin J, Emery S, Hoy J, Workman C, Doong N, Freund J, Cooper DA. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 18: 1029-36, 2004.
24. McComsey GA, Ward DJ, Hessenthaler SM, Sension MG, Shalit P, Lonergan JT, Fisher RL, Williams VC, Hernandez JE. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 38: 263-70, 2004.
25. Neumann T, Woiwod T, Neumann A, Miller M, Von BC, Volbracht L, Esser S, Brockmeyer N, Gerken G, Erbel R. Cardiovascular risk factors and probability for cardiovascular events in HIV-infected patients - part III: age differences. Eur J Med Res 9: 267-72, 2004.
26. Neumann T, Woiwod T, Neumann A, Ross B, Von BC, Volbracht L, Brockmeyer NH, Gerken G, Erbel R. Cardiovascular risk factors and probability for cardiovascular events in HIV-infected patients. Part II: gender differences. Eur J Med Res 9: 55-60, 2004.
27. Neumann T, Woiwoid T, Neumann A, Miller M, Ross B, Volbracht L, Brockmeyer N, Gerken G, Erbel R. Cardiovascular risk factors and probability for cardiovascular events in HIV-infected patients: part I. Differences due to the acquisition of HIV-infection. Eur J Med Res 8: 229-35, 2003.
28. Palella FJ, Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853-60, 1998.
29. Polgreen PM, Putz D, Stapleton JT. Inaccurate glycosylated hemoglobin A1C measurements in human immunodeficiency virus-positive patients with diabetes mellitus. Clin Infect Dis 37: e53-e56, 2003.
30. Ricart W, Fernandez-Real JM, del PM, Mascaro J, Garcia-Bragado F. The cause of elevated glycosylated haemoglobin concentrations in AIDS. AIDS 7: 1274-5, 1993.
31. Saint-Marc T, Partisani M, Poizot-Martin I, Bruno F, Rouviere O, Lang JM, Gastaut JA, Touraine JL. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 13: 1659-67, 1999.
32. Schooley RT, Ruane P, Myers RA, Beall G, Lampiris H, Berger D, Chen SS, Miller MD, Isaacson E, Cheng AK. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 16: 1257-63, 2002.
33. Gallant JE, Parish M, Keruly J, Moore R. Changes in renal function in patients treated with Tenofovir DF (TDF) compared to nucleoside reverse transcriptase inhibitors (NRTIs). 3rd IAS Conference 2005, Rio de Janeiro 24-27 July 2005, Abstract TuPe2.3C18.